COMBO Dual Therapy Stent: A Long term Solution to Vessel Restoration.
Latest results further support excellent healing benefits of World’s first and only Dual Therapy Stent .
Genoa, Italy, 17th October, 2014 - Latest data presented on the COMBO Dual Therapy Stent, provides further evidence to support the long-term safety and efficacy of the stent in the treatment of coronary artery disease. The latest results demonstrate the excellent healing benefits of the COMBO Stent, with data supporting early stent coverage and control of neo-intimal proliferation. Unique neointima regression from nine to 24 months was also observed which has not been seen with other drug eluting stents (DES).
Key findings from the EGO COMBO and REMEDEE First in Man (FIM) trials were presented on October 16th, at the 35th Congresso Nazionale della Societa' Italiana di Cardiologia Invasiva (GISE) conference in Genoa, Italy by Prof. Giuseppe De Luca, of the Eastern Piedmont University in Novara, Italy.
“Clinical data gathered from the trials to date is very encouraging, particularly around the unique 24-month neointima regression phenomenon,” said Prof. De Luca. “This new data validates what we have seen in clinical practice and illustrates the COMBO Stent’s ability to deliver long-term true vessel healing.”
Prof. De Luca, Co-Principal Investigator of the REDUCE trial, also announced the initiation of this multi-center trial designed to evaluate the potential for shorter-term dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients. REDUCE will for the first time evaluate the safety of shorter (three months) DAPT in ACS patients with the COMBO Stent across centers in Europe and Asia. “I believe that the unique EPC technology featured on the COMBO Stent may safely enable us to reduce the duration of DAPT and, as a result, decrease the risk of bleeding and ensure high compliance among patients,” said Prof. De Luca.